Dr. Tung Shu, MD

Dr. Shu practices at Houston Plastic and Craniofacial Surgery Center in Houston, Texas.

Dr. Shu's NPI, 1841229523, was assigned on July 3, 2006. Dr. Shu graduated from UTMB Health in 1996. Dr. Shu holds Texas license L4122.

Dr. Shu's primary practice is Houston Plastic and Craniofacial Surgery Center, at 6400 Fannin St, Houston, TX 77030 in Harris County. The practice phone is (713) 791-0700.

Dr. Shu's primary practice is Houston Plastic and Craniofacial Surgery Center in Houston, Texas. Dr. Shu is also affiliated with Memorial Hermann Greater Heights Hospital. The medical group on file is UT Physicians. Dmand AI also links Dr. Shu to 4 more hospitals and 1 group practice or clinic, each named with a free account.

Dmand AI tracks the electronic health record (EHR) system at each site where Dr. Shu practices, 6 sites in all. Vendor and product names are available with a free account.

Urology is Dr. Shu's primary specialty in the NPI Registry, under taxonomy code 208800000X. Dr. Shu is board certified in urology by the American Board of Urology. Dr. Shu is licensed in Texas.

Dmand AI lists bladder disease, enlarged prostate, enlarged prostate transurethral surgery (TURP), kidney cysts, kidney removal surgery, kidney stone disease, pelvic prolapse and prostate cancer among the conditions Dr. Shu treats.

CMS data shows 4,060 Medicare services from Dr. Shu across 21 procedure codes in 2024, for 544 Medicare patients. Medicare paid $165,100 for them.

CMS counts 544 Medicare patients who saw Dr. Shu in 2024. The largest group is 65 to 74, with 246 patients. 75% of them have high blood pressure, and 75% have high cholesterol. 8% are also on Medicaid. Their average risk score is 2.34, where 1.00 is the Medicare average, so they are sicker than most Medicare patients.

Across all payers, Dmand AI patient panel data puts Dr. Shu's median patient age at 70, with 24% women.

In 2024, Dr. Shu wrote 2,358 Medicare Part D claims for 557 patients. 84% of them were for generic drugs. CMS names the drug for 2,161 of them, across 33 drugs with 11 or more claims each, at $372,736 in total drug cost. In 2023, CMS named 2,097 claims across 33 drugs.

CMS publishes a Merit-based Incentive Payment System (MIPS) score of 84 out of 100 for Dr. Shu for performance year 2024, reported as part of a group. Dr. Shu accepts Medicare assignment, so Medicare's approved amount is taken as full payment. CMS counts 16 procedures of prostate resection by Dr. Shu, more than 74% of the clinicians it reports for that procedure.

Dmand AI links 15 papers to Dr. Shu, published from 2002 to 2025. The most frequent topics are Abscess, Laparoscopy and Antibodies, Monoclonal. Dr. Shu has published most often in Urology. Dr. Shu's most frequent co-authors are Eduardo Orihuela, MD, Run Wang, MD and Carlos A. Angel, MD.

CMS Open Payments shows 330 general payments to Dr. Shu from 58 drug and device companies from 2016 to 2025. Food and beverage make up the largest share, 56% of the total. AxoGen paid the most, $6,245.

Dmand AI lists 3 awards for Dr. Shu, most recently Regional Top Doctor in 2014.

Dr. Shu graduated from UTMB Health in 1996.

Dr. Shu is in network with 21 carriers, including Elevance, Aetna and United Healthcare. PPO plans come from the most carriers, 14. Check the plan with the practice before a visit.